Adaptive Biotechnologies
ADPT
206 hedge funds and large institutions have $5.41B invested in Adaptive Biotechnologies in 2020 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 96 increasing their positions, 43 reducing their positions, and 28 closing their positions.
281% more call options, than puts
Call options by funds: $20.2M | Put options by funds: $5.3M
123% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 43
39% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 28
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
11% more capital invested
Capital invested by funds: $4.89B → $5.41B (+$523M)
5% more funds holding
Funds holding: 196 → 206 (+10)
2.4% more ownership
Funds ownership: 79.63% → 82.03% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$59.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$46.9M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$36.1M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$30M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$84.1M |
| 2 |
HM
HealthCor Management
New York
|
-$16.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.4M |
| 4 |
BlackRock
New York
|
-$12.8M |
| 5 |
RSWM
Robertson Stephens Wealth Management
San Francisco,
California
|
-$8.82M |
ADPT Hedge Fund Activity: Q3 2020 in Review
206 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q3 2020, worth a combined $5.41B — up 11% from $4.89B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new ADPT positions and 28 closed out — a net gain of 11 holders — while 96 added to existing stakes and 43 trimmed.
The largest buyer was Vanguard Group, adding an estimated $59.9M. The largest seller was Matrix Capital Management Company, cutting an estimated $84.1M.
- 206 institutional investors held Adaptive Biotechnologies (ADPT) as of Q3 2020, up from 196 in Q2 2020.
- Funds reported $5.41B of Adaptive Biotechnologies stock for Q3 2020, up 11% quarter-over-quarter.
- 39 funds opened new Adaptive Biotechnologies positions in Q3 2020 and 28 closed out, a net change of +11 holders.
- The largest Adaptive Biotechnologies buyer in Q3 2020 was Vanguard Group, an estimated $59.9M added.
- The largest Adaptive Biotechnologies seller in Q3 2020 was Matrix Capital Management Company, an estimated $84.1M sold.
Based on aggregated 13F filings for Q3 2020.